多原发膀胱癌与单发膀胱癌中P53、Bcl-2、C-erbB-2、EGFR的表达及临床意义

目的:研究多原发膀胱癌与单发膀胱癌中P53?Bcl-2?C-erbB-2?表皮生长因子受体(epidermal growth factor receptor,EGFR)的表达情况,探讨其临床意义,为多原发膀胱癌的临床诊断?鉴别诊断及靶向治疗提供实验依据?方法:运用免疫组化方法检测多原发膀胱癌15例,单发膀胱癌15例(临床分期?病理分级与多原发膀胱癌相同),正常膀胱组织15例,3组共45例中P53?Bcl-2?C-erbB-2?EGFR的表达情况,比较其阳性表达率及表达程度的差异?结果:多原发膀胱癌及单发膀胱癌中P53?Bcl-2?C-erbB-2?EGFR的阳性表达均高于正常膀胱组织(P < 0.05),多原发膀胱癌组织中P53?Bcl-2的阳性表达高于单发膀胱癌组织(P < 0.05),而C-erbB-2?EGFR的阳性表达低于单发膀胱癌组织(P < 0.001)?结论:多原发膀胱癌与单发膀胱癌组织中P53?Bcl-2?C-erbB-2?EGFR表达有差异;联合检测P53?Bcl-2?C-erbB-2?EGFR对于多原发膀胱癌的诊断及鉴别诊断具有一定临床价值,也为多原发膀胱癌的靶向治疗提供了可能?

Expressions and significances of P53,Bcl-2,C-erbB-2 and EGFR in patients with multiple primary bladder cancers and single bladder cancers

Objective:To study the expression and clinical features of P53,Bcl-2,C-erbB-2 and (epidermal growth factor receptor,EGFR) in multiple primary bladder cancers and single bladder cancers,and provide evidence for diagnosis and targeted treatment of multiple primary bladder cancer. Methods:Immunohistochemical SP methods were used to detect the expression of P53,Bcl-2,C-erbB-2 and EGFR in 15 patients with multiple primary bladder cancers,15 patients with single bladder cancers(The clinical stage and pathological grade of patients with single bladder cancers were similar to those with multiple primary bladder cancers.) and 15 patients with normal bladder,the differences of the expression of P53,Bcl-2,C-erbB-2 and EGFR in each group were analyzed. Results:The positive expressions of P53,Bcl-2,C-erbB-2 and EGFR in patients with multiple primary bladder cancers and single bladder cancers were significantly higher than those in patients with normal bladders(P < 0.05). The positive expressions of P53 and Bcl-2 in multiple primary bladder cancer tissues were higher than those in single bladder cancer tissues(P < 0.05),while the positive expressions of C-erbB-2 and EGFR in multiple primary bladder cancer tissues were significantly lower than those in single bladder cancer tissues (P < 0.001). Conclusion:The positive expressions of P53,Bcl-2,C-erbB-2 and EGFR were different between multiple primary bladder cancers and single bladder cancers (P < 0.05). The combined detection of P53,bcl-2,C-erbB-2 and EGFR is valuable for the clinical diagnosis and identification of multiple primary bladder cancers. This study provides the possibility of the targeting therapy of multiple primary bladder cancers.